{
  "id": 7536157,
  "title": "PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer",
  "url": "https://urgent.news/2026/09/15/papillon-trial-amivantamab-plus-chemotherapy-adds-months-of-survival",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T11:00:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-papillon-trial-amivantamab-chemotherapy-months.html"
  },
  "original_language": "en",
  "account": "The landmark PAPILLON trial, conducted at Georgetown University's Lombardi Comprehensive Cancer Center and 231 other international sites, has shown that the drug amivantamab, added to chemotherapy, significantly improves survival for patients with a rare form of lung cancer. This form of lung cancer is difficult to treat and makes up about 1-2% of all advanced non-small cell lung cancers (NSCLC) in the U.S. Historically, the median overall survival for patients with this type of cancer was around 1.5 to 2 years. However, the trial revealed that with amivantamab plus chemotherapy, the median overall survival increased to 34.3 months, nearly 3 years. Although the statistical significance of this improvement was not reached due to the trial's limited power, the crossover between treatment groups made the benefit more pronounced. Amivantamab is a bispecific antibody, a new class of targeted therapies designed to bind to two different targets. The trial also highlights the importance of next-generation sequencing, a genomic testing method that identifies rare alterations like the EGFR exon 20 insertion mutation, allowing physicians to match patients with therapies specifically designed for their tumors.",
  "summary": "Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.",
  "key_points": [
    "Amivantamab plus chemotherapy extends survival by 3 years in rare lung cancer",
    "Amivantamab is a bispecific antibody targeting two different cancer markers",
    "Next-generation sequencing identifies EGFR exon 20 insertion mutation for personalized treatment"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}